Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 8/20 | 0.52 |
| ▸ | CCR9 | P51686 | 9/20 | 0.51 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12910764 | 0.90 | MEN1 (0.43) | CCR2CCR9GPR35MEN1KMT2A | |
| SCHEMBL3660500 | 0.90 | CCR2 (0.52) | CCR2GPR35MEN1KMT2A | |
| SCHEMBL941496 | 0.85 | NOD2 (0.56) | CCR9MEN1KMT2A | |
| SCHEMBL3655296 | 0.82 | CCR9 (0.54) | CCR2CCR9GPR35 | |
| SCHEMBL3725600 | 0.81 | CCR2 (0.51) | CCR2CCR9GPR35MEN1KMT2A | |
| SCHEMBL15361987 | 0.81 | CCR2 (0.71) | CCR2CCR9GPR35 | |
| SCHEMBL939880 | 0.81 | CCR2 (0.56) | CCR2CCR9GPR35 | |
| SCHEMBL14556303 | 0.80 | CCR2 (0.46) | CCR2CCR9GPR35 | |
| SCHEMBL940444 | 0.79 | CCR9 (0.61) | CCR2CCR9GPR35 | |
| SCHEMBL3659137 | 0.79 | CCR9 (0.41) | CCR2CCR9GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2235014-B1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-10-09 | — | — | EP | disclosed |
| US-8399491-B2 | Derivatives of indole-2-carboxamides and of azaindole-2-carboxamides substituted with a silanyl group, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-03-19 | — | — | US | disclosed |
| EP-2235003-B1 | DERIVATIVES OF INDOLE 2-CARBOXAMIDES AND AZAINDOLE 2-CARBOXAMIDES SUBSTITUTED BY A SILANYLE GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2012-12-19 | — | — | EP | disclosed |
| US-20110009365-A1 | DERIVATIVES OF INDOLE-2-CARBOXAMIDES AND OF AZAINDOLE-2-CARBOXAMIDES SUBSTITUTED WITH A SILANYL GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
| EP-2235014-A2 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-10-06 | — | — | EP | disclosed |
| EP-2235003-A1 | DERIVATIVES OF INDOLE 2-CARBOXAMIDES AND AZAINDOLE 2-CARBOXAMIDES SUBSTITUTED BY A SILANYLE GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009112677-A2 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009109710-A1 | DERIVATIVES OF INDOLE 2-CARBOXAMIDES AND AZAINDOLE 2-CARBOXAMIDES SUBSTITUTED BY A SILANYLE GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009365-A1 | DERIVATIVES OF INDOLE-2-CARBOXAMIDES AND OF AZAINDOLE-2-CARBOXAMIDES SUBSTITUTED WITH A SILANYL GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | IDO2, INMT, IDO1 | CCR2 1212/4885CCR9 2789/4885GPR35 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.